Incyte DMA

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

When researching a stock like Incyte, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from INCY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for INCY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the INCY 200 day moving average ("INCY 200 DMA"), while one of the most popular "shorter look-backs" is the INCY 50 day moving average ("INCY 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Incyte.

10 Most Oversold S&P 500 Stocks

10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying

10 ETFs With Most Upside To Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active S&P Call & Put Options

Quotes delayed 20 minutes

Free INCY Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Incyte (INCY) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

IQV DMA
ISRG DMA
JNJ DMA
LH DMA
LLY DMA
MCK DMA
MDT DMA
MMM DMA
MOH DMA
MRK DMA
More Healthcare companies »

Join StockDMA.com
Create a FREE account to continue
Already have an account? LOG IN

Full Disclaimer & Terms of Use and Privacy Policy. Important: If you are in Canada or the European Union, you must click here for alternate registration page.

✓

Immediate access to our INCY DMA page as well as our full coverage universe of stocks

✓

Complimentary report on monthly dividend paying stocks

✓

Daily market updates from our Contrarian Outlook team

✓

Join FREE with just your email address

Welcome back!

StockDMA.com and parent company BNK Invest, Inc. value our relationship with you and would like to continue providing accurate and tailored communications to fit your investing needs. To receive our publications and other relevant communications, Canada's anti-spam legislation (''CASL'') and the European Union's General Data Protection Regulation (''GPDR'') requires us to obtain your express consent. Please provide your consent to continue. In any email we send, you will be given the option to withdraw your consent or unsubscribe from any or all of our newsletters or publications at any time.

Incyte DMA | www.StockDMA.com | Copyright © 2019 - 2024, All Rights Reserved